ArticleExperimental and therapeutic medicine2014
Resolvin E1 reduces hepatic fibrosis in mice with
Article in Experimental and therapeutic medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Endogenous Lipid Signals in Energy Homeostasis and Fibrosis.Biomolecules · 2026Review
- Review
- PriorFrontiers in veterinary science · 2024Article
- Omega-3 Lipid Mediators: Modulation of the M1/M2 Macrophage Phenotype and Its Protective Role in Chronic Liver Diseases.International journal of molecular sciences · 2023Review
- Immunomodulatory and biological properties of helminth-derived small molecules: Potential applications in diagnostics and therapeutics.Frontiers in parasitology · 2022Review
- Review
- Pro-Resolving Lipid Mediator Resolvin E1 Mitigates the Progress of Diethylnitrosamine-Induced Liver Fibrosis in Sprague-Dawley Rats by Attenuating Fibrogenesis and Restricting Proliferation.International journal of molecular sciences · 2020Article
- Limited potential of resolvin D1 in treatment of cholestatic liver fibrosis.Hepatobiliary surgery and nutrition · 2020Article
- The Role of Endogenous Eicosapentaenoic Acid and Docosahexaenoic Acid-Derived Resolvins in Systemic Sclerosis.Frontiers in immunology · 2020Review
- Pathological mechanisms and therapeutic outlooks for arthrofibrosis.Bone research · 2019Article
- Function of Pro-Resolving Lipid Mediator Resolvin E1 in Type 2 Diabetes.Critical reviews in immunology · 2018Review
- Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors.Molecular aspects of medicine · 2017Review
- Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Review
- Chemokine-Like Receptor 1 mRNA Weakly Correlates with Non-Alcoholic Steatohepatitis Score in Male but Not Female Individuals.International journal of molecular sciences · 2016Article
- Protective effects of extracts from Pomegranate peels and seeds on liver fibrosis induced by carbon tetrachloride in rats.BMC complementary and alternative medicine · 2015Article
- Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs.Advances in nutrition (Bethesda, Md.) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to investigate whether resolvin E1 (RvE1) protects against hepatic fibrosis in a murine model of liver fibrosis induced by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.